|Articles|November 5, 2015

Pediatric Drug Development & Therapeutics

Author(s)DIA

DIA’s Editor-in-Chief Stephen P. Spielberg, MD, PhD, FAAP, and Ronald Portman, MD, FAAP, discuss the Pediatric Drug Development & Therapeutics series of articles and how they can help inform the future of pediatric drug development on DIA’s podcast channel, Driving Ideas to Action.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

Pediatric Drug Development & Therapeutics

Related Content

U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report

Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI

Ovarian Cancer: Closing Gaps and Advancing Care with RWD

Pharmaceutical Executive Daily: Alnylam Pharmaceuticals and Inceptive Nucleics Announce 3 Year Strategic Collaboration

Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive

Trending on PharmExec

Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive

U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report

Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI

Navigating PBM Pitfalls: Protecting Revenue in a Complex Rebate Landscape

Pharmaceutical Executive Daily: New FDA Draft Guidance Targets Gene Therapy Submission Burden